Trial Profile
Double-blind placebo-controlled study of subcutaneous immunotherapy in birch pollen allergic patients
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Jul 2017
Price :
$35
*
At a glance
- Drugs Birch pollen allergy immunotherapy (Primary)
- Indications Asthma; Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Stallergenes Greer plc
- 02 Jan 2007 New trial record.